.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Moving Toward Precision Medicine in Adult Acute Myeloid Leukemia

EP. 1: Risk-directed Approaches to AML Therapy

January 11th 2017

EP. 2: CPX-351 for Older Patients with AML

January 11th 2017

EP. 3: MRD Assessment and Consolidation in AML

January 11th 2017

EP. 4: Maintenance Therapy for AML

January 11th 2017

EP. 5: Emerging Role of FLT3 Inhibitors in AML: Midostaurin

January 11th 2017

EP. 6: Quizartinib in AML

January 11th 2017

EP. 7: IDH1/2 inhibitors for AML

January 11th 2017

EP. 8: Vosaroxin/Cytarabine in AML

January 11th 2017

EP. 9: Venetoclax in AML

January 11th 2017

EP. 10: Emerging Therapies for Acute Myeloid Leukemia

January 11th 2017